COVID-19 Vaccine and Thrombotic Thrombocytopenic Purpura (TTP): A Rare Association
Table of Contents
A recent study has identified a link between the CoronaVac inactivated COVID-19 vaccine and a rare but serious condition called acquired immune thrombotic thrombocytopenic purpura (TTP). This marks the first reported association between TTP and inactivated COVID-19 vaccines.While TTP incidence initially decreased in 2020, it saw a rise in 2021-2022, coinciding with increased COVID-19 vaccination rates, suggesting a possible connection.Prompt diagnosis and treatment with plasma exchange are crucial for managing thes cases.
Understanding Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic Thrombocytopenic Purpura (TTP) is a life-threatening blood disorder characterized by the formation of small blood clots throughout the body. These clots can obstruct blood flow to vital organs, leading to serious complications. Key features of TTP include:
* Thrombocytopenia: A low platelet count, increasing the risk of bleeding.
* Microangiopathic Hemolytic Anemia: Damage to red blood cells as they pass through the small clots.
* Neurological Symptoms: Can range from headache and confusion to seizures and stroke.
* Fever: Often present in acute cases.
TTP is caused by a deficiency in the ADAMTS13 enzyme, which is responsible for breaking down a protein called von Willebrand factor. When ADAMTS13 is deficient, von Willebrand factor accumulates, leading to clot formation. Acquired TTP, the type linked to the CoronaVac vaccine, develops due to the presence of antibodies that inhibit ADAMTS13 activity. https://www.nhlbi.nih.gov/health/thrombotic-thrombocytopenic-purpura-tpp
The study, published in Frontiers of medicine https://doi.org/10.1007/s11684-023-1054-2, details cases of TTP following vaccination with coronavac, an inactivated virus COVID-19 vaccine. researchers observed a delayed onset of TTP, typically weeks to months after vaccination.
The researchers hypothesize that the relatively milder immune response triggered by inactivated vaccines, compared to mRNA vaccines, may contribute to the rarity and delayed onset of TTP. Inactivated vaccines use a killed version of the virus to stimulate an immune response, while mRNA vaccines deliver genetic instructions for the body to produce a viral protein.
It’s critically important to note that the incidence of TTP following vaccination remains extremely low. Data from other countries showed varying incidence rates of TTP during the pandemic. For example, the UK reported 11 cases in 2020, 6 in 2021, 16 in 2022, and 17 in 2023. https://www.gov.uk/drug-safety-update/thrombotic-thrombocytopenia-syndrome-tps-following-covid-19-vaccination-update-on-risk-assessment
Diagnosis and Treatment
Early diagnosis and treatment are critical for improving outcomes in TTP. The primary treatment is plasma exchange, a procedure that removes the patient’s plasma (containing the inhibitory antibodies) and replaces it with donor plasma (containing functional ADAMTS13). https://www.mayoclinic.org/diseases-conditions/thrombotic-thrombocytopenic-purpura/diagnosis-treatment/drc-20352830
Other treatments may include:
* Immunosuppressants: To suppress the immune system and reduce antibody production.
* Corticosteroids: To reduce inflammation.
* Caplacizumab: A medication that inhibits von Willebrand factor.
Key Takeaways
* TTP is a rare but serious blood disorder.
* A link has been established between the CoronaVac inactivated COVID-19 vaccine and acquired TTP.
*
Keep reading